Sichuan Kelun-Biotech Biopharmaceutical (6990) Fundamentals 2026 — Revenue Analysis | SniperIQ
Sichuan Kelun-Biotech Biopharmaceutical (6990) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sichuan Kelun-Biotech Biopharmaceutical's market cap?
Sichuan Kelun-Biotech Biopharmaceutical (6990) has a market capitalization of approximately HK
What is Sichuan Kelun-Biotech Biopharmaceutical's P/E ratio?
Sichuan Kelun-Biotech Biopharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sichuan Kelun-Biotech Biopharmaceutical?
Sichuan Kelun-Biotech Biopharmaceutical runs a net profit margin of -18.6%, a gross margin of 71.9%, and an operating margin of -16.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sichuan Kelun-Biotech Biopharmaceutical generate?
Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.1B for fiscal year 2025, with net income of -¥382M and earnings per share (EPS) of -1.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sichuan Kelun-Biotech Biopharmaceutical pay a dividend?
Sichuan Kelun-Biotech Biopharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sichuan Kelun-Biotech Biopharmaceutical financially healthy?
Sichuan Kelun-Biotech Biopharmaceutical carries a debt-to-equity ratio of 0.02x and a current ratio of 5.13x, with a market beta of -0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sichuan Kelun-Biotech Biopharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sichuan Kelun-Biotech Biopharmaceutical (6990) the key facts are: market cap HK
Track Sichuan Kelun-Biotech Biopharmaceutical's full fundamentals live
Get Sichuan Kelun-Biotech Biopharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.